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DERIVING SEVERITY INDEX FOR RHEUMATOID ARTHRITIS FROM 
HEALTH CARE CLAIMS DATA
Baser O1, Gust C2, Akin C3
1STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
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OBJECTIVES: Health care claims databases do not contain information about disease 
severity. The goal of this study was to develop a severity index for rheumatoid arthritis 
(SIFRA) for private health care claims data using a previously developed claims-based 
index from the Veteran’s Administration (VA) Health System and rheumatoid arthritis 
medical records-based index of severity (RARBIS). METHODS: We extracted the 
following variables related to rheumatoid arthritis from the claims data: total number 
of synthetic disease-modifying anti-rheumatic drugs (DMARDs), total number of 
biological DMARDs, tests for C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR) ordered, rehabilitation visits, rheumatology visits, Felty’s syndrome and 
Sjorgen’s syndrome, pulmonary, soft tissue nodules, joint surgery, number of platelet 
counts and chemical panels ordered, and rheumatoid factors testing. A linear regres-
sion model was used to create the severity score. The severity score was compared 
with RARBIS and currently-used comorbidity scores to proxy severity in outcomes 
research studies related with rheumatoid arthritis. RESULTS: According to the Akaike 
Information Criterion (AIC), Bayesian Information Criterion (BIC), log likelihood 
function, R-squared values and average squared prediction error, SIFRA performed 
better than RARBIS, Charlson Comorbidity Score (CCI), Elixhauser comorbidity score 
and Chronic disease score. Spearman correlation with RARBIS was 0.65 and signiﬁ-
cant. However, the correlation with the Charlson Comorbidity Index (0.1, p = 
0.6521), Elixhauser Index (0.15, p = 0.5312) and Chronic disease score (0.13, p = 
0.6011) were low and insigniﬁcant. CONCLUSIONS: Controlling disease severity is 
crucial in retrospective studies. Comorbidity scores are inadequate to be proxy vari-
able. SIFRA, at least for rheumatoid arthritis, controls for disease severity better than 
any other commonly used measure.
NEUROLOGICAL DISORDERS – Clinical Outcomes Studies
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CLINICAL AND PHARMACY UTILIZATION OUTCOMES WITH BRAND 
TO GENERIC ANTIEPILEPTIC UTILIZATION IN PATIENTS WITH 
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OBJECTIVES: To determine if switching from select branded to generic equivalent 
antiepileptic drug (AED) in patients with epilepsy is associated with adverse outcomes 
or with utilization changes that may proxy for adverse outcomes. METHODS: A 
retrospective cohort study using a large health insurance plan claims database was 
undertaken comparing patients with ICD-9-CM codes of epilepsy or non-febrile 
convulsions who switched from brand to generic equivalent AED after 6 months 
(switch cohort) to those who remained on the brand (non-switch cohort). Potential 
non-switch subjects were matched 1:1 to 745 phenytoin switch patients, 995 lamotrig-
ine switch patients and 399 divalproex switch patients. Outcomes measured included 
the event rate ratio (ERR) of the composite of all-cause emergency department (ED) 
visits or hospitalizations and the incidence rate ratio (IRR) of discontinuation of the 
index AED, change in dose of index AED or addition of another AED. RESULTS: 
The switch vs. non-switch cohorts did not demonstrate differences in ED visits or 
hospitalizations for the studied AEDs (ERR for phenytoin 0.96, 95% CI 0.80–1.16; 
ERR for lamotrigine 0.97, 95% CI 0.80–1.17; ERR for divalproex 0.83, 95% CI 
0.66–1.06). Compared with non-switchers, the phenytoin switch cohort had greater 
incidence of AED utilization changes (IRR 1.85, 95% CI 1.50–2.29). Lamotrigine and 
divalproex showed no differences in AED utilization between the switchers and non-
switchers (IRR for lamotrigine 1.00, 95% CI 0.84–1.19; IRR for divalproex 1.02, 
95% CI, 0.88–1.42). CONCLUSIONS: Lamotrigine or divalproex brand to generic 
switching was not associated with increased incidence of ED visits or hospitalizations 
or utilization changes compared with patients remaining on the branded product. 
Brand to generic switching of phenytoin was not associated with an increase in ED 
visits or hospitalizations but was associated with greater numbers of index drug dis-
continuations, dose changes or therapy augmentations.
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THE VALUE OF A PREDICTIVE DIAGNOSTIC BLOOD TEST IN 
MULTIPLE SCLEROSIS (MS)
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OBJECTIVES: To assess the cost effectiveness of gMS®Pro EDSS, a test designed to 
identify MS patients with a high likelihood of progressing fast and in need of more 
aggressive treatment. METHODS: A literature-based discrete-event simulation follows 
patients visiting their physicians at deﬁned EDSS score deteriorations. At each visit, 4 
therapies are considered: three less aggressive/less expensive therapies (assumed 
monthly cost of $2,000/patient) and a more aggressive/more expensive therapy 
(assumed monthly cost of $3,000/patient) associated with severe side effects. The more 
agressive therapy is only considered cost effective in fast deteriorating patients. The 
expected cost effectiveness of each therapy was calculated using a Markov model 
(using EDSS scores as health states) and applying a Bayesian updating process con-
sidering the likelihood that the patient is “fast deteriorating” and/or responds to 
therapy. The model compares patients’ costs and quality of life when the gMS®Pro 
EDSS test is used vs. when it is not. The estimated sensitivity and speciﬁcity of 
gMS®Pro EDSS were 65.18% and 84.09%, respectively based on clinical trail results. 
The costs of all non-medication costs were based on Kobelt et al. RESULTS: Using 
the test, in comparison to not using the test, in a MS population containing 25% of 
patients who progress fast results in more frequent (25.18% vs. 24.24%) and earlier 
(2.24 years on average) use of aggressive therapy. The test is estimated to result in a 
gain of 0.11 QALY’s and to be economically dominant up to a price of $2640 (cost 
of medication is estimated to increase by $2984 which is offset by savings of $2704 
of other direct medical costs and $2920 of production losses). CONCLUSIONS: The 
gMS®Pro EDSS is likely to be a cost effective addition in the identiﬁcation of the 
optimal therapy for MS patients.
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GASTROINTESTINAL DISORDERS IN PATIENTS WITH PARKINSON’S 
DISEASE: A DOUBLE-EDGED SWORD
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OBJECTIVES: A majority of patients with Parkinson’s disease (PD) eventually develop 
gastrointestinal disorders (GID), which can impair the onset of symptom relief by PD 
drugs. There was a need to better understand the rate and consequences of GID 
amongst patients diagnosed with PD. METHODS: A two years matched retrospective 
cohort study was performed in a registered Pharmetrics® datacut, a US claims data-
base containing records on demographics, diagnoses, procedures, provider, prescrip-
tions and claims that span from 2000 to 2008. Patients with at least two prior 
diagnoses of Parkinson’s Disease, with continuous prescriptions of levodopa or dopa-
mine agonists between September 1, 2005 and September 1, 2006 were selected. 
Patients with and without GID were matched by age, gender, comorbidities, and 
treatment regime. Their respective emerging health outcomes were followed-up for 
two years. Outcomes were deﬁned on the basis of a literature review and included 
neuropsychiatric, motor, urogenital disturbances, health care utilization and related 
costs. RESULTS: In the datacut, GID incidence among patients with PD increased 
over time to stabilize at 75% at 92 months. 485 patients with PD and GID were 
matched to 485 controls with PD but without GID. GID was associated with signiﬁ-
cantly higher rates of neuropsychiatric and motor disorders, including psychosexual 
dysfunction (RR = 8, p = 0.05), anxiety (RR = 1.61, p < 0.01), depression (RR = 1.28, 
p = 0.03), ataxia (RR = 1.24, p = 0.03), pain (RR = 1.28, p < 0.01), movement dis-
orders (RR = 1.39, p < 0.01), urinary incontinence (RR = 1.43, p = 0.02), and risk of 
fall (RR = 1.44, p = 0.04). ER admissions (ratio = 1.42, p < 0.01), number of concur-
rent drugs (ratio = 1.06, p = 0.04) and PD and non-PD health care costs (ratios = 1.13 
and 1.12, p < 0.01 respectively) increased during the observation period in the GID 
patients. CONCLUSIONS: GID have a substantial deleterious effect on major PD-
related clinical and societal outcomes. Non oral formulations of PD drugs (apomor-
phine or L-dopa pumps or rotigotine) may offer a good opportunity to bypass 
gastrointestinal tract, and accordingly maximize patient response to treatment.
NEUROLOGICAL DISORDERS – Cost Studies
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OBJECTIVES: Estimate total (direct plus indirect) cost savings with 1200 mg of gaba-
pentin enacarbil (GEn), a new RLS therapy. For formulary access, new medications 
must often show cost savings of drug. Before approval, data are hard to generate. This 
study provides one way of generating estimated pre-launch cost savings per patient. 
METHODS: Two data sources are used: pooled efﬁcacy results from two 12-week, 
randomized, double-blind, placebo-controlled trials (Protocol XP052 and XP053, 
Clinical Trials.gov NCT00298623 and NCT00365352) of GEn and resource use/
economic data from a 2007 community survey. The survey collected RLS-related 
ofﬁce (physician, emergency room, hospital) laboratory tests, prescription and non-
prescription medication use. Indirect costs came from the Work Productivity and 
Activity Impairment (WPAI) questionnaire. Severity class costs were derived by using 
the International Restless Legs Syndrome Questionnaire. Estimated savings were 
derived by applying the proportion of patients moving between severity categories to 
cost differences between those categories. RESULTS: A total of 191 patients received 
GEn and completed baseline/Week 12 assessments. From baseline to Week 12, 48.2% 
with moderate RLS severity moved to mild severity, 26.7% moved from severe to mild 
and 8.4% moved from severe to moderate. The mean (SD) 3-month direct RLS-related 
costs among mild, moderate, severe and very severe patients were $48.90 ($113.7), 
$108.60 ($210.2), $264.60 ($391.30) and $428.3 ($689.40), respectively. Mean (SD) 
3-month indirect costs due to RLS-related lost productivity were $460.20 ($838.20), 
$1462.50 ($2513.90), $3699.30 ($3471.60) among mild, moderate and severe 
patients (no very severe reported working). Using sensitivity analyses, the per-patient, 
